LDAcoop : Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro
Molecular Oncology · 2025
DOI: 10.1002/1878-0261.70185 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Nikko Brix und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University Hospital, LMU München, Munich, Germany. Hauptthemen laut MEDLINE: Nonlinear Dynamics. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung.
Abstract (Originalsprache)
The limiting dilution assay (LDA) is a key method to quantify clonogenic cells with self‐renewing capacity in vitro , crucial for preclinical cancer research and therapy response assessment. It estimates the frequency of individual clonogenic, stem‐like cells within a population based on their ability to form colonies with ≥50 cells at limiting cell numbers. Standard LDA analysis relies on linear, single‐hit Poisson models, yet clonogenic growth under single‐cell conditions often involves cooperative or competitive dynamics, violating this linearity assumption. Here, we present a modeling framework incorporating non‐linear population dynamics into LDA analysis and introduce LDAcoop, an R‐based tool for universal quantification of clonogenic cells in LDA formats. Across multiple cancer cell types, we benchmarked LDA against the colony formation assay (CFA) and show that LDA outperforms CFA, especially for patient‐derived organoids, suspension cultures, and higher throughput applications. This renders the LDA format particularly suitable for larger‐scale pharmacogenomic screening and drug sensitivity testing in complex models. Our results establish LDA and LDAcoop as versatile, scalable tools for robust quantification of clonogenic growth, supporting preclinical drug development and molecular precision oncology research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, University Hospital, LMU München, Munich, Germany.
- Research Unit Translational Metabolic Oncology (TMO), Institute for Diabetes and Cancer (IDC), Helmholtz Diabetes Center, Helmholtz Munich, Neuherberg, Germany.
- Joint Heidelberg-IDC Translational Diabetes Program, Department of Inner Medicine I, Heidelberg University Hospital, Heidelberg, Germany.
- German Center for Diabetes Research (DZD), Neuherberg, Germany.
- Bavarian Center for Cancer Research (BZKF) partner site Munich, Munich, Germany.
- Department of Internal Medicine II, University Hospital, LMU München, Munich, Germany.
ORCID-Profile: Nikko Brix, Kirsten Lauber
Förderung
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung
Zitieren
APA
Brix, N., Samaga, D., Gehr, K., Dankó, B., Schumann, M., Drexler, G., Alnatsha, A., Beyer, G., Mahajan, U., Selmansberger, M., Mayerle, J., Belka, C., Zitzelsberger, H., & Lauber, K. (2025). LDAcoop : Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro. Molecular Oncology. https://doi.org/10.1002/1878-0261.70185
Vancouver
Brix N, Samaga D, Gehr K, Dankó B, Schumann M, Drexler G, et al. LDAcoop : Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro. Molecular Oncology. 2025. doi:10.1002/1878-0261.70185
BibTeX
@article{Brix2025,
author = {Brix, Nikko and Samaga, Daniel and Gehr, Katharina and Dankó, Benedek and Schumann, Mohamed and Drexler, Guido and Alnatsha, Ahmed and Beyer, Georg and Mahajan, Ujjwal and Selmansberger, Martin and Mayerle, Julia and Belka, Claus and Zitzelsberger, Horst and Lauber, Kirsten},
title = {LDAcoop : Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro},
journal = {Molecular Oncology},
year = {2025},
doi = {10.1002/1878-0261.70185}
}
EUVIMED